Hyperparathyroidism

49,800views

Hyperparathyroidism

IM EOR

IM EOR

Angina pectoris
Premature atrial contraction
Premature ventricular contraction
Supraventricular arrhythmias: Pathology review
Ventricular tachycardia
Ventricular fibrillation
Atrial flutter
Atrial fibrillation
Wolff-Parkinson-White syndrome
Atrioventricular nodal reentrant tachycardia (AVNRT)
Long QT syndrome and Torsade de pointes
Stable angina
Unstable angina
Prinzmetal angina
Class I antiarrhythmics: Sodium channel blockers
Dilated cardiomyopathy
Hypertrophic cardiomyopathy
Restrictive cardiomyopathy
Heart failure
Diabetes mellitus
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Insulins
Diabetes insipidus
Hypercalcemia
Hypocalcemia
Hypernatremia
Hyponatremia
Hyperparathyroidism
Hypoparathyroidism
Hypercholesterolemia: Clinical
Lipid-lowering medications: Statins
Coronary artery disease: Clinical
Endocarditis
Class II antiarrhythmics: Beta blockers
Peptic ulcer
Acute pancreatitis
Chronic pancreatitis
GERD, peptic ulcers, gastritis, and stomach cancer: Pathology review
Gastritis
Thiazide and thiazide-like diuretics
ACE inhibitors, ARBs and direct renin inhibitors
ECG cardiac infarction and ischemia
Abnormal heart sounds
Pulmonary valve disease
Tricuspid valve disease
cGMP mediated smooth muscle vasodilators
Sarcoidosis
Mycobacterium tuberculosis (Tuberculosis)
Pneumonia
Myocardial infarction
Adrenergic antagonists: Beta blockers
Hyperthyroidism
Hypothyroidism
Thyroid storm
Hypertension: Clinical
Class IV antiarrhythmics: Calcium channel blockers and others
Calcium channel blockers
Asthma
Emphysema
Pericarditis and pericardial effusion
Cardiac tamponade
Antiplatelet medications
Primary adrenal insufficiency
Pheochromocytoma
Cushing syndrome
Ischemic stroke
Bell palsy
Multiple sclerosis
Guillain-Barre syndrome
Bundle branch block
Migraine
Tension headache
Cluster headache
Syncope: Clinical
Transient ischemic attack
Non-steroidal anti-inflammatory drugs
Fibromyalgia
Gout
Systemic lupus erythematosus
Iron deficiency anemia
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Pulmonary hypertension
Pneumothorax
Lung cancer
Pulmonary embolism
Pseudomonas aeruginosa
Clostridium botulinum (Botulism)
Vitamin B12 deficiency
Influenza virus
Sickle cell disease (NORD)
Treponema pallidum (Syphilis)
Clostridium tetani (Tetanus)
Borrelia burgdorferi (Lyme disease)
Protein C deficiency
Folate (Vitamin B9) deficiency
Factor V Leiden
Protein S deficiency
Antithrombin III deficiency
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Paget disease of bone
Antiphospholipid syndrome
Rheumatoid arthritis
Ulcerative colitis
Candida
Cryptococcus neoformans
Positive and negative predictive value
Cirrhosis
Thyroid cancer
Shock
Neisseria gonorrhoeae
Pituitary adenoma
Seizures and epilepsy
Bordetella pertussis (Whooping cough)
Prostatitis
Meningitis
Vibrio cholerae (Cholera)
Testicular torsion
Epididymitis
Polycystic kidney disease
Polymyalgia rheumatica
Polymyositis
Hemorrhoid
Portal hypertension
Varicocele
Varicella zoster virus
Irritable bowel syndrome
Cytomegalovirus
Acid reducing medications
Concussion and traumatic brain injury
Hepatocellular carcinoma
Renal artery stenosis
Rheumatic heart disease
Cor pulmonale
Gastroesophageal reflux disease (GERD)
Sjogren syndrome
Huntington disease
Scleroderma
Acute cholecystitis
Viral hepatitis
Appendicitis
Diverticulosis and diverticulitis
Kidney stones
Acute pyelonephritis
Chronic pyelonephritis
Lower urinary tract infection
Glaucoma
Ascending cholangitis
Non-urothelial bladder cancers
Hydronephrosis
Celiac disease
Benign prostatic hyperplasia
Prerenal azotemia
Renal azotemia
Postrenal azotemia
Chronic kidney disease
Poststreptococcal glomerulonephritis
Membranous nephropathy
Membranoproliferative glomerulonephritis
IgA nephropathy (NORD)
Acute tubular necrosis
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Alport syndrome
Parkinson disease
Encephalitis
Delirium
Dementia with Lewy bodies
Vascular dementia
Frontotemporal dementia
Alzheimer disease
Adult brain tumors
Acid-base map and compensatory mechanisms
Erectile dysfunction
Acromegaly
Esophageal web
Esophageal disorders: Clinical
Colorectal cancer
Rapidly progressive glomerulonephritis
Goodpasture syndrome
Esophageal cancer
Gastric cancer
Esophagitis: Clinical
HIV (AIDS)
Anemia of chronic disease
Beta-thalassemia
Anemia of chronic disease
Alpha-thalassemia
Multiple myeloma
Shigella
Toxoplasma gondii (Toxoplasmosis)
Histoplasmosis
Rickettsia rickettsii (Rocky Mountain spotted fever) and other Rickettsia species
Pneumonia: Clinical

Transcript

Watch video only

With hyperparathyroidism, “hyper” refers to over, and “parathyroid” refers to the parathyroid glands, so hyperparathyroidism refers to a condition where there is an overproduction of parathyroid hormone.

Parathyroid hormone comes from the parathyroid glands which are buried within the thyroid gland, and their main job is to keep blood calcium levels stable.

Now, the majority of the extracellular calcium, the calcium in the blood and interstitium, is split almost equally between two groups - calcium that is diffusible and calcium that is not diffusible.

Diffusible calcium is small enough to diffuse across cell membranes and is separated into two subcategories.

The first is free-ionized calcium, which is involved in all sorts of cellular processes like neuronal action potentials, contraction of skeletal, smooth, and cardiac muscle, hormone secretion, and blood coagulation, all of which are tightly regulated by enzymes and hormones.

The second category is complexed calcium, which is where the positively charged calcium is ionically linked to tiny negatively charged molecules like oxalate, which is a small anion that are normally found in our blood in small amounts.

The complexed calcium forms a molecule that’s electrically neutral but unlike free-ionized calcium it’s not useful for cellular processes.

Both of these are called diffusible because they’re small enough to diffuse across cell membranes.

Finally there’s the non-diffusible calcium which is bound to negatively charged proteins like albumin.

The resulting protein-calcium complex is too large and charged to cross membranes, leaving this calcium also uninvolved in cellular processes.

Changes in the body’s levels of extracellular calcium are detected by a surface receptor in parathyroid cells that’s called the calcium-sensing receptor.

These changes affect the amount of parathyroid hormone that’s released by the parathyroid gland.

The parathyroid hormone gets the bones to release calcium, it gets the kidneys to reabsorb more calcium so it's not lost in the urine, and it synthesizes calcitriol, which is also known as 1,25-dihydroxycholecalciferol, or active vitamin D.

Active vitamin D then goes on to cause the gastrointestinal tract to increase calcium absorption.

Altogether, these effects help to keep the extracellular levels of calcium within a narrow range that’s between 8.5 to 10 mg/dl.

So there are three types of hyperparathyroidism - primary, secondary, and tertiary.

In primary hyperparathyroidism, the parathyroid gland is responsible for the problem, because it makes parathyroid hormone independently of the calcium level.

Excess parathyroid hormone stimulates osteoclasts to break down bone and makes the kidneys hold on to calcium and get rid of phosphate - resulting in hypercalcemia and hypophosphatemia.

The excess calcium makes neurons less excitable, which leads to slower muscle contractions, and diminishes neuron firing in the central nervous system.

It also causes hypercalciuria - excess loss of calcium in urine - which can lead to dehydration. This is because there is just too much calcium to be reabsorbed by the kidneys.

Most often, primary hyperparathyroidism is caused by a single parathyroid adenoma, or benign tumor, which happens either because of a genetic mutation in a single cell or because of an inherited disorder like multiple endocrine neoplasia, which affects the parathyroid, pancreas, and pituitary glands.

Rarely, primary hyperparathyroidism is caused by hyperplasia, where parathyroid cells divide excessively causing growth of the glands, or by a parathyroid carcinoma, a cancerous tumor.

In secondary hyperparathyroidism, the parathyroid gland is normal, but it makes excess parathyroid hormone in response to chronic hypocalcemia - a low level of calcium - from another cause.

Key Takeaways

Hyperparathyroidism is a condition in which the parathyroid glands produce too much parathyroid hormone (PTH), which regulates calcium levels in the blood. Hyperparathyroidism can be primary, secondary, or even tertiary.

Primary hyperparathyroidism usually results from PTH secretion by a parathyroid adenoma. It is characterized by excess PTH that leads to high blood calcium levels (hypercalcemia), bone mass loss, kidney stones, and other health problems, such as psychiatric issues.

Secondary hyperparathyroidism develops when there are conditions like chronic kidney disease, which can lead to low calcium, high phosphate, and low vitamin D levels. It is mainly characterized by osteodystrophy, in which there is bone weakening associated with bone pain and deformation.

Finally, there is tertiary hyperparathyroidism, which occurs because of chronic secondary hyperparathyroidism from kidney disease. This leads to hypercalcemia and phosphate imbalances.

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Harrison's Endocrinology, 4E" McGraw-Hill Education / Medical (2016)
  6. "Vitamin D Deficiency and Secondary Hyperparathyroidism in the Elderly: Consequences for Bone Loss and Fractures and Therapeutic Implications" Endocrine Reviews (2001)
  7. "Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients" Cochrane Database of Systematic Reviews (2014)